ONCONOVA THERAPEUTICS INC (ONTX) Stock News
NASDAQ:ONTX - Nasdaq - US68232V8019 - Common Stock - Currency: USD
ONTX Latest News, Press Relases and Analysis
Traws Pharma Announces New Employee Inducement Grants
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards...
Traws Pharma Announces New Employee Inducement Grants
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024...
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Translational science to characterize pathways impacted by rigosertib may help to guide future clinical studies and combination treatment regimen for difficult-to-treat cancers
Onconova stock falls 10% on preclinical data for lymphoma drug (NASDAQ:ONTX)
Onconova (ONTX) stock fell 10% after the biotech company presented preclinical data for its drug candidate narazaciblib in the treatment of mantle cell lymphoma. Read more here.
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a look at the biggest pre-market stock movers worth watching for Monday morning!
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s...
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
Onconova presenting at NobleCon19 Dec 4-5 in Boca Raton, FL...
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Tuesday, November 14, 2023
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft...
Onconova Expands Leadership Team with Two Key Appointments
Onconova Expands Leadership Team: Victor Moyo named Chief Medical Officer, Meena Arora joins as Vice President Global Medical Affairs and R&D ...
Onconova Expands Leadership Team with Two Key Appointments
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023Additional studies support broad potential, especially in cyclin-dependent cancers ...
Encouraging Rigosertib Data Presented at EADV as Late Breaker
Reporting responses in patients with RDEB-associated SCC, a devastating disease with a significant unmet need
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage...
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Steven Fruchtman, M.D., President & CEO, will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023.
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023